Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aclidinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 17/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 16/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | TACR1 | P25103 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclidinium SCHEMBL72141 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72140 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72693 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL29351588 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72694 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73281 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73282 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL71791 | 0.95 | CHRM3 (0.91) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73023 | 0.95 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73022 | 0.95 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | METOPI PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | claimed |
| US-20260102344-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | KINDEVA DRUG DELIVERY LP (US) | 2026-04-16 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| WO-2022038365-A2 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | WO | claimed |
| CN-111297837-B | Preparation method of dry powder inhalant | 上海方予健康医药科技有限公司 | 2022-02-22 | — | — | CN | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| WO-2022029307-A1 | INHALER SYSTEM | NORTON (WATERFORD) LIMITED (IE) | 2022-02-10 | — | — | WO | claimed |
| EP-3946268-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | The Regents of The University of California (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2022023515-A1 | COMBINATION THERAPY FOR INHALATION ADMINISTRATION | CHEMO RESEARCH , S.L. (ES) | 2022-02-03 | — | — | WO | claimed |
| US-7897617-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA S.A. (ES) | 2011-03-01 | — | — | US | claimed |
| US-20100234333-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2010-09-16 | — | — | US | claimed |
| US-7750023-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. | 2010-07-06 | — | — | US | claimed |
| US-20080221155-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL PRODESFARMA, S.A. (ES) | 2008-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | CHRM3 347/4885CHRM2 277/4885CHRM1 157/4885 |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | CCR1, CCR2, CBR1 | CHRM3 724/4885CHRM2 438/4885CHRM1 265/4885 |
| US-20260102344-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | ADRA1D, CHRND, ADRB2 | CHRM3 63/4885CHRM2 108/4885CHRM1 165/4885 |
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | CHRM3 4/4885CHRM2 3/4885CHRM1 1/4885 |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | SET, FHIT, FZD7 | CHRM3 674/4885CHRM2 1870/4885CHRM1 1501/4885 |
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | CHRM3 727/4885CHRM2 745/4885CHRM1 945/4885 |
| US-20080221155-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | CHRM3, CHRM4, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
| US-20100234333-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM4, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.